Abhishek Maiti

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 325 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi et al. · Journal of Clinical Oncology · 2021 · 321 citations · Full text

Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclax

Kunhwa Kim, Abhishek Maiti, Sanam Loghavi et al. · Cancer · 2021 · 149 citations · Full text

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Nicholas J. Short, Hagop M. Kantarjian, Sanam Loghavi et al. · The Lancet Haematology · 2018 · 115 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +11

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

Abhishek Maiti, Wei Qiao, Koji Sasaki et al. · American Journal of Hematology · 2020 · 99 citations · Full text